Blood type no barrier? study tests liver transplant success across ABO barriers

NCT ID NCT07703735

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Seoung Hoon Kim Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks back at 371 adults who received a living donor liver transplant for hepatocellular carcinoma (a type of liver cancer) to see whether receiving a liver from a donor with an incompatible blood type affects long-term survival or cancer recurrence. Researchers compared overall survival and recurrence patterns between ABO-incompatible and ABO-compatible transplant recipients over a 12-year period. The goal is to understand whether using mismatched blood types is a safe and effective option for more patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: living donor liver transplantation (ABO-incompatible vs ABO-compatible)
What this could lead to: If ABO-incompatible transplants prove as effective as compatible ones, more liver cancer patients could receive life-saving transplants regardless of blood type.
What could go wrong: This is a retrospective, single-center study, so results may not apply broadly. ABO-incompatible transplants carry higher risks of rejection and complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC) LIVER TRANSPLANTATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.